DRIO vs RARE · rev $10.8M vs rev $350.0M
DarioHealth Corp (DRIO) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
DarioHealth Corp (DRIO) is a health information services company listed on NASDAQ.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported DRIO revenue for 2026-06-30 was $10.8M. Net income was -$16.2M. Revenue was up 92.7% from 2026-03-31 to 2026-06-30. DRIO currently screens at market cap $52.1M.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
DRIO currently screens at market cap $52.1M. RARE currently screens at market cap $2.79B.
Not investment advice. Open the DRIO and RARE stock pages for the full models.
Not investment advice.